Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
TOR/mTOR Antibody, Alexa Fluor™ 594, Novus Biologicals™

Rabbit Polyclonal Antibody
Supplier: Novus Biologicals NB100240AF594
Description
TOR/mTOR Polyclonal specifically detects TOR/mTOR in Human, Rat samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunocytochemistry.Specifications
TOR/mTOR | |
Polyclonal | |
Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunocytochemistry | |
EC 2.7.11.1, FK506 binding protein 12-rapamycin associated protein 1, FK506 binding protein 12-rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP12-rapamycin complex-associated protein, FLJ44809, FRAP, FRAP1FKBP12-rapamycin complex-associated protein 1, FRAP2, Mammalian target of rapamycin, Mechanistic target of rapamycin, mechanistic target of rapamycin (serine/threonine kinase), mTOR, RAFT1, rapamycin and FKBP12 target 1, rapamycin associated protein FRAP2, Rapamycin target protein 1, RAPT1FKBP-rapamycin associated protein, serine/threonine-protein kinase mTOR | |
Rabbit | |
Affinity Purified | |
Autophagy, Cancer, Cell Cycle and Replication, DNA Repair, Hypoxia, Macroautophagy, MAP Kinase Signaling, mTOR Pathway, Phospho Specific, Signal Transduction, Translation Control | |
2475.0 | |
Store at 4°C in the dark. |
Western Blot, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunocytochemistry | |
Alexa Fluor 594 | |
50 mM sodium borate with 0.05% sodium azide | |
MTOR | |
The immunogen recognized by this antibody maps to a region between residue 200 and 250 of human Mammalian Target of Rapamycin using the numbering given in entry NP_004949.1 (GeneID 2475). | |
100 μL | |
Primary | |
Human, Rat | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction